Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
4
-
Total 13F shares, excl. options
-
4.67M
-
Shares change
-
-164K
-
Total reported value, excl. options
-
$96.7M
-
Value change
-
-$3.65M
-
Number of buys
-
2
-
Number of sells
-
-2
-
Price
-
$21.46
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q4 2023
5 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q4 2023.
Denali Therapeutics Inc. - Common Stock (DNLI) has 4 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.67M shares
of 145M outstanding shares and own 3.22% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (14.3M shares), BlackRock Inc. (11.5M shares), VANGUARD GROUP INC (10.8M shares), WELLINGTON MANAGEMENT GROUP LLP (7.27M shares), Temasek Holdings (Private) Ltd (6.9M shares), Crestline Management, LP (5.66M shares), STATE STREET CORP (5.49M shares), TAKEDA PHARMACEUTICAL CO LTD (4.21M shares), Capital Research Global Investors (2.91M shares), and GEODE CAPITAL MANAGEMENT, LLC (2.66M shares).
This table shows the top 4 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.